Acute Upper Respiratory Infection Clinical Trial
Official title:
Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection
Phase IV trial,Single-arm, multi-centre clinical trial to assess the efficacy and safety of Fuganlin Oral Liquid in children with acute upper respiratory infection
Low-dose group of Fuganlin Oral Liquid:dosage from 5 to 10 ml;
High-dose group of Fuganlin Oral Liquid:dosage from 10 to 20 ml;
Treatment for 1 week.Patients who were recovered within 1 week can withdrawal at any time.
Research purpose:
1. Evaluate the safety and efficacy of Fuganlin oral Liquid when expanding the designated
indications(Qi deficiency wind-heat syndrome to wind-heat syndrome) .
2. Explore the relationship between elevated white blood cells and efficacy, age and
efficacy, dose and efficacy,While treating with Fuganlin oral Liquid in children with
acute respiratory infection.
3. Observe the antiviral and immunomodulatory effects of Fuganlin oral Liquid.
4. Provide data to support the clinical medicine guidelines and labels amendment of
Fuganlin oral Liquid.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01694329 -
Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada
|
N/A | |
| Completed |
NCT04651491 -
Treatment of Influenza and ARVI in Children by Kagocel ®
|
||
| Recruiting |
NCT04252963 -
Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase)
|
Phase 4 | |
| Withdrawn |
NCT01814293 -
Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)
|
N/A | |
| Completed |
NCT02622659 -
The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection)
|
Phase 4 | |
| Completed |
NCT01779271 -
Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection
|
Phase 3 | |
| Recruiting |
NCT02539277 -
A Post-marketing Research on Jinyebaidu Granule in Treating Patients With Acute Upper Respiratory Infection
|
Phase 4 | |
| Completed |
NCT02983019 -
Treatment of Influenza in Routine Clinical Practice
|
N/A |